CD40 is a costimulatory receptor on antigen-presenting cells that functions as a therapeutic immune-activation target, and agonistic stimulation can drive antitumor immunity. In orthotopic PDAC-bearing mice, agonistic CD40 antibody therapy induced immune activation and significantly prolonged survival, and the effect was further studied in combination with IL1R1 blockade. CD40 is also engaged by the tumor-targeted agonist kk2269, a bispecific antibody targeting CD40 on APCs, highlighting its role in APC-directed immunotherapy. Beyond pancreatic cancer, CD40 was prioritized as a candidate drug target for b cell malignancy and was identified among protein-disease associations in hodgkin lymphoma. Recent proteome-wide Mendelian randomization and cancer-immunotherapy studies support CD40 as a clinically relevant immune checkpoint-like costimulatory axis with translational potential.
Pancreatic cancer
- Agonistic CD40 antibody therapy induced immune activation and significantly prolonged survival in orthotopic PDAC-bearing mice. (PMID:41935073)
- A 2026 Scientific Reports study (PMID:41935073) reported that IL1R1 blockade augments CD40 agonist-mediated immunity in pancreatic cancer. (PMID:41935073)
- CD40 was the target of the tumor-targeted agonist kk2269, which engaged antigen-presenting cells in this setting. (PMID:41989931)
Cancer immunotherapy / APC targeting
- CD40 is an antigen-presenting cell target engaged by kk2269, a bispecific antibody designed to activate APCs. (PMID:41989931)
- The CD40 agonist axis was linked to immune activation and antitumor synergy with docetaxel in a 2026 Cancer Science paper. (PMID:41989931)
- Agonistic CD40 antibody therapy was associated with prolonged survival, supporting CD40 as an immunostimulatory therapeutic target. (PMID:41935073)
Hematologic malignancy
- CD40 was prioritized as a candidate drug target for b cell malignancy in a proteome-wide Mendelian randomization study. (PMID:41859349)
- The same study identified CD40 among protein-disease associations in hodgkin lymphoma. (PMID:41859349)
- These findings support CD40 as a disease-associated protein with potential therapeutic relevance in B-cell cancers. (PMID:41859349)